See OV’s CTO Thomas Jensen at TEDx Boseman on April 9:th
As previously announced, Oncology Venture’s CTO, Thomas Jensen is one of the speakers at the TEDxBozeman 2016 this coming Saturday, April 9, in Bozeman, Montana, USA. The headline for his speech is “Fly Fishing, Photography & Solving Cancer… Same Same but Different!”. He will be talking about the parallels he sees between photography, fly fishing and the art of solving riddles within cancer research with the help of Drug Response Predictor - DRP™)
According to schedule, Thomas will go on stage at 10.56 Central European time, and the speech is broadcasted live here:
http://livestream.com/TEDx/Bozeman2016
The platform Drug Response Predictor - DRP™, which is being used by Oncology Venture, was created in 2004 at Medical Prognosis Institute, MPI, in Denmark. It is a cutting edge technology, where cell line array data from individual tumor tissue of cancer patients is translated to information relevant for treating the patient’s cancer disease.
With the help of DRP™, Oncology Venture can better the odds within development of anticancer drugs. Screening patients provides predicitons of which individuals are most likely to respond positive to a certain drug candidate, and these patients can then be entered in clinical testing of the drug.
At MPI, DRP™ is being used for develpoment of individually adapted cancer treatment.
Thomas Jensen is the Chief Technology Officer for Oncology Venture and Medical Prognosis Institute. He is pioneering the bridging of good science, effective laboratory techniques, and bioinformatics to advance the biology of cancer. Amongst Thomas' accolades are his inventions of molecular biological guidelines and techniques for high-quality RNA processing.
This allows for high-resolution analysis of cancer patients' biopsies. His inventions are an important foundation of MPI's Drug Response Predictor platform – a high-resolution bioinformatics tool, that predicts the sensitivity and resistance of anticancer drugs.
What is TEDx?
For ideas worth spreading, TED has created a program called TEDx - a series of local, self-organized events that bring people together to share a TED-like experience. This weekend’s event is called TEDxBozeman, where x = independently organized TED event. At TEDxBozeman, TEDTalks videos and live speakers will be combined to spark deep discussion and connection in a specific group. If you are nearby Bozeman on April 9th, come see Thomas Jensen and the other interesting speakers inspire the TEDxBozeman 2016 theme of “Confluence.” If you are elsewhere, but still want to enjoy these interesting talks, you can do so live via the link above, or at the TEDx website whenever suitable. If you want to know more about this weekend’s event and the other speakers, see:
http://www.tedxbozeman.com/speakers/
For more information on Oncology Venture AB, please contact:
Peter Buhl Jensen, CEO
Phone: +45 21 60 89 22
E-mail: pbj@buhloncology.com
http://www.oncologyventure.com/
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.